Sunshine Biopharma Inc. warrant financials
$0.0540+74.19%
Close Sep 18, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M |
| Gross profit | $12.3M | $10.7M | $8.3M | $1.7M |
| Gross margin | 33.8% | 30.6% | 34.6% | 39.0% |
| Operating income | -$6.2M | -$5.8M | -$4.8M | -$27.0M |
| Net income | -$6.0M | -$5.1M | -$4.5M | -$26.7M |
| Net margin | −16.5% | −14.7% | −18.7% | −615.4% |
| Diluted EPS | $-14.40 | $-73.20 | $-3513.60 | $-35200.00 |
| EBITDA | -$3.8M | -$4.7M | -$4.6M | -$8.6M |
| Operating cash flow | -$5.3M | -$12.5M | -$8.6M | -$5.2M |
| Free cash flow | -$5.5M | -$14.2M | -$8.7M | -$5.4M |
| Diluted shares | 0.4M | 0.1M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $9.1M | $9.7M | $16.3M | $21.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $30.1M | $30.6M | $27.3M | $29.2M |
| Total liabilities | $7.0M | $7.1M | $6.1M | $7.6M |
| Shareholders' equity | $23.0M | $23.5M | $21.2M | $21.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology